US FDA’s Overloaded Advanced Therapies Office Eyes Organizational, Communication Changes

 
• By Sue Sutter

Office of Tissues and Advanced Therapies seeks to optimize its organizational structure and adopt more group-level communications, instead of one-on-one interactions with sponsors, to keep up with the massive growth in cell and gene therapies, director Wilson Bryan says.

Tree branches
Some of the branches of FDA's Office of Tissues and Advanced Therapies have grown so large they are unmanageable. • Source: Alamy

More from Cell & Gene Therapies

More from Advanced Technologies